Investigational drug · Phase 2
BRIMOCHOL PF eye drops
Also called: CARBACHOL PF eye drops, Brimonidine tartrate eye drops
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Presbyopia, Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "BRIMOCHOL PF eye drops"
First trial start
2024
Jul 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BRIMOCHOL PF eye drops", any sponsor or status.
Conditions studied
As listed on its trial records.
- Presbyopia
- Recurrent Ovarian Cancer
- Folate Receptor-Alpha Positive
Approved drugs for the same conditions: Ovarian cancer · Oncology · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "BRIMOCHOL PF eye drops" as an intervention, largest first.
- Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic PresbyopiaPivotal-lookingCompleted
Visus TherapeuticsAcademic, hospital or other
NCT05135286 · 629 participants · Start Mar 15, 2022 · Primary completion Mar 13, 2025
Drug: BRIMOCHOL™ PF; Carbachol PF and 1 more · For: Presbyopia
Sites: Chandler, Arizona; Phoenix, Arizona; Sun City, Arizona · 42 sites in all
- Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic PresbyopiaPivotal-lookingCompleted
Visus TherapeuticsAcademic, hospital or other
NCT05270863 · 182 participants · Start Mar 30, 2022 · Primary completion Mar 17, 2023
Drug: BRIMOCHOL™ PF; Carbachol PF and 1 more · For: Presbyopia
Sites: Glendale, California; Rancho Cordova, California; Jacksonville, Florida · 15 sites in all
- Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia PatientsPivotal-lookingRecruiting
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.Industry
NCT06948357 · 119 participants (planned) · Start Mar 24, 2025 · Primary completion Sep 30, 2025
Drug: BRIMOCHOL PF eye drops; CARBACHOL PF eye drops; Brimonidine eye drops; Placebo · For: Presbyopia
Sites: Wenzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Allergic Contact Dermatitis from Brimonidine Tartrate Eye Drops: A Rare Dermatological Reaction with a "Teardrop Streak Sign".
Konisky H, Gregory AN, Huho A · Dermatitis 2025
- Topical brimonidine for the management of facial erythema in rosacea: a histological, histometric, and immunohistochemical study.
El-Domyati M, Rezk AF, Nasif G, et al. · Int J Dermatol 2023
- Effects of brimonidine tartrate 0.2 and 0.15% ophthalmic solution on the static and dynamic pupil characteristics.
Yang J, Zhang X, Zhong M, et al. · Front Med (Lausanne) 2023
- Interstitial Keratitis with Lipid Keratopathy Mimicking Corneal Opacity Induced by Brimonidine Tartrate Eye Drops.
Kasuya Y, Sano I, Makino S · Klin Monbl Augenheilkd 2020
- High Permeability and Intercellular Space Widening With Brimonidine Tartrate Eye Drops in Cultured Stratified Human Corneal Epithelial Sheets.
Hashimoto Y, Yokoo S, Usui T, et al. · Cornea 2018
- Natural Bioadhesive Biodegradable Nanoparticle-Based Topical Ophthalmic Formulations for Management of Glaucoma.
Ibrahim MM, Abd-Elgawad AH, Soliman OA, et al. · Transl Vis Sci Technol 2015
Also in development for Presbyopia
- phentolamine vehiclePhase 32 trials
Opus Genetics, Inc · Mesopic Vision, Night Vision Loss, Presbyopia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.